Cancer Research Institute (CRI) shared a post on LinkedIn:
“For CRI Scientific Advisory Council Associate Director Dr. Jedd Wolchok of Weill Cornell Medicine, immunotherapy has always been a question not of “if” but “when,” Princeton Alumni Weekly describes.
“I saw that it wasn’t a question of whether it was real, but a matter of making the clinical successes more frequent,” he expresses.